12 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jul 2032. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jul 2032
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends no later than Dec 2037 · Low confidence
Also notable
Ends Jul 2032 · High confidence
Methylphenidate-Prodrugs, Processes of Making and Using the Same
US 10,584,112
Cited by 8 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2037. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Methylphenidate-Oxoacid Conjugates, Processes of Making and Using the Same
US 9,079,928
The most cited patent in this portfolio, cited by 22 later US patents, top 25% of utility patents granted in 2015 in our data. Protection runs to 2032.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 14, 2027The maintenance fee for Methylphenidate-Oxoacid Conjugates, Processes of Making and Using the Same (US 9,079,928) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.
- 2 fees due Sep 10, 2027
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methylphenidate-Prodrugs, Processes of Making and Using the Same | 9 in force | to Dec 2037 |
| Methylphenidate-Oxoacid Conjugates, Processes of Making and Using the Same | 3 in force | to Jul 2032 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,079,928 | Methylphenidate-Oxoacid Conjugates, Processes of Making and Using the Same In force · High confidence | In force | High confidence | |
| US 9,453,037 | Methylphenidate-Prodrugs, Processes of Making and Using the Same In force · High confidence | In force | High confidence | |
| US 10,231,960 | Methylphenidate-Prodrugs, Processes of Making and Using the Same In force · High confidence | In force | High confidence | |
| US 11,505,537 | Compositions Comprising Methylphenidate-Prodrugs, Processes of Making and Using the Same In force · Low confidence | In force | Low confidence | |
| US 10,584,112 | Methylphenidate-Prodrugs, Processes of Making and Using the Same In force · Low confidence | In force | Low confidence | |
| US 10,584,113 | Methylphenidate-Prodrugs, Processes of Making and Using the Same In force · Low confidence | In force | Low confidence | |
| US 10,759,778 | Methylphenidate-Prodrugs, Processes of Making and Using the Same In force · Low confidence | In force | Low confidence | |
| US 10,858,341 | Compositions Comprising Methylphenidate-Prodrugs, Processes of Making and Using the Same In force · Low confidence | In force | Low confidence | |
| US 10,954,212 | Compositions Comprising Methlphenidate-Prodrugs, Processes of Making and Using the Same In force · Low confidence | In force | Low confidence | |
| US 10,954,213 | Compositions Comprising Methylphenidate-Prodrugs, Processes of Making and Using the Same In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 12: 2 applications pending · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed